Delytact scores a first with Japanese approval for malignant glioma

14 June 2021

Japanese drugmaker Daiichi Sankyo (TYO: 4568) says it has received conditional and time-limited approval from the Japan Ministry of Health, Labor and Welfare (MHLW) for Delytact (teserpaturev/G47∆), an oncolytic virus, for the treatment of patients with malignant glioma.

Delytact previously received SAKIGAKE and Orphan Drug designations from the MHLW for this indication and is now the first oncolytic virus to be approved in any region of the world for treatment of malignant glioma or any type of primary brain cancer. Daiichi Sankyo has been collaboratively developing Delytact with Dr Tomoki Todo of the Institute of Medical Science, the University of Tokyo, and is the marketing authorization holder of Delytact in Japan.

Continued approval for this indication may be contingent upon verification and description of clinical benefit and safety in a post-market comparative clinical study. Delytact is not approved for any use outside of Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK